CHINESE JOURNAL OF MEDICINAL GUIDE >
Clinical Efficacy of Different Doses of Atorvastatin Combined with Antiplatelet Drugs on Lacunar Infarction
Received date: 2024-11-04
Revised date: 2025-09-18
Accepted date: 2025-12-03
Online published: 2025-12-17
Objective： To analyze and compare the clinical efficacy of different doses of atorvastatin combined with antiplatelet drugs in the treatment of lacunar infarction （LI）.Methods： A total of 98 patients with LI admitted to our hospital from January 2022 to June 2023 were selected as the research subjects， and were divided into the low-dose group （n=49） and the conventional-dose group （n=49） by random number table method and remainder grouping method. Both groups of patients were given aspirin enteric-coated tablets 100 mg·d-1 orally， and the conventional-dose group was combined with atorvastatin calcium tablets 20 mg·d-1 orally， while the low-dose group conbined with atorvastatin calcium tablets 10 mg·d-1 orally. Both groups of patients were treated for 24 weeks. The clinical efficacy of the two groups of patients was recorded. The neurological deficits ［National Institutes of Health stroke scale （NIHSS）］， cognitive function ［Montreal cognitive assessment scale （MoCA）］， lipid metabolism indicators ［triglyceride （TG）， total cholesterol （TC）， low-density lipoprotein cholesterol （LDL-C）， high-density lipoprotein cholesterol （HDL-C）］， serum indicators ［homocysteine （Hcy）， high sensitive C-reactive protein （hs-CRP）］ were compared between the two groups of patients before treatment and after 24 weeks of treatment. The adverse reactions during treatment were evaluated. Taking one year of treatment and stroke recurrence as the follow-up endpoints to compare the difference in stroke recurrence-free survival time between the two groups.Results： After 24 weeks of treatment， the total effective rates in the conventional-dose group and low-dose group were 97.87% and 87.23% respectively （P>0.05）， and the total incidence rates of adverse reactions were 10.64% and 4.26% respectively （P>0.05）. The NIHSS scores of both groups of patients were lower than those before treatment （P<0.05） while the MoCA scores were higher than those before treatment （P<0.05）， but there were no statistic differences between the two groups （P>0.05）. After 24 weeks of treatment， the levels of TG， TC， LDL-C， Hcy and hs-CRP in both groups decressed compared with those before treatment （P<0.05）， and the above indicators in conventional-dose group were lower than those in low-dose group （P<0.05）； HDL-C levels rose in both groups （P<0.05）， and the levels in the conventional-dose group were higher （P<0.05）. After 1 year of treatment， there were 2 cases （4.26%） of stroke recurrence in the conventional-dose group and 4 cases （8.51%） in the low-dose group. There were no statistical differences in stroke recurrence rate and stroke recurrence-free survival time between the two groups （both P>0.05）.Conclusion： Although antiplatelet drugs combined with conventional dose 20 mg·d-1 atorvastatin calcium tablets are superior to low dose 10 mg·d-1 atorvastatin calcium tablets in lipid regulation， anti-inflammation and protection of vascular endothelial function， the clinical efficacy and the effect of controlling stroke recurrence in the prognosis of LI of the two doses of atorvastatin calcium tablest are similar， and both have relatively few adverse reactions， which can provide reference data for the formulation of clinical LI treatment regimen.
DONG Luchen, LI Yan
.
Clinical Efficacy of Different Doses of
Atorvastatin Combined with Antiplatelet Drugs on Lacunar Infarction
［1］ Wardlaw JM， Woodhouse LJ， Mhlanga II， et al. Isosorbide mononitrate and cilostazol treatment in patients with symptomatic cerebral small vessel disease：the lacunar intervention trial-2 （LACI-2） randomized clinical trial［J］.JAMA Neurol， 2023，80（7）：682-692.
［2］ Deguchi I， Takahashi S. Pathophysiology and optimal treatment of intracranial branch atheromatous disease［J］.J Atheroscler Thromb， 2023，30（7）：701-709.
［3］ Wang H， Liu S， Zhou C， et al. Fatal hepatic failure following atorvastatin treatment： a case report［J］.Medicine （Baltimore）， 2023，102（19）：e33743.
［4］ Yu Y， Wang L， Zhu X， et al. Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction［J］.World J Diabetes， 2021，12（12）：2096-2106.
［5］ 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国脑小血管病诊治指南2020［J］.中华神经科杂志，2022，55（8）：807-818.
［6］ Adams HP Jr， Davis PH， Leira EC， et al. Baseline NIH stroke scale score strongly predicts outcome after stroke： a report of the Trial of Org 10172 in Acute Stroke Treatment （TOAST）［J］.Neurology， 1999，53（1）：126-131.
［7］ Kang JM， Cho YS， Park S， et al. Montreal cognitive assessment reflects cognitive reserve［J］.BMC Geriatr， 2018，18（1）：261-268.
［8］ Williams EI， Betterton RD， Stanton JA， et al. Oatp （organic anion transporting polypeptide）-mediated transport： a mechanism for atorvastatin neuroprotection in stroke［J］.Stroke， 2023， 54（11）：2875-2885.
［9］ Chen G， Wang Z， Song W， et al. Effects of long-term regular oral aspirin combined with atorvastatin to prevent ischemic stroke on human gut microbiota［J］.Eur J Pharmacol， 2023，951（1）：e175800.
［10］ 甄海宁.对于自发性严重深部幕上脑出血采用去骨瓣减压术联合最佳药物治疗与单独最佳药物治疗的比较：一项随机对照临床试验［J］.中华神经外科疾病研究杂志，2025，19（1）：98.
［11］ Thomas RG， Kim JH， Kim JH， et al. Treatment of ischemic stroke by atorvastatin-loaded PEGylated liposome［J］.Transl Stroke Res， 2024，15（2）：388-398.
［12］ 梁夏炎，廉应聪，周忠，等.基于AMPK/mTOR信号通路探究阿托伐他汀对川崎病冠状动脉内皮细胞损伤的影响［J］.安徽医学，2025，46（7）：805-810.
［13］ Bilski AE， Aparicio HJ， Gutierrez J， et al. Antiplatelet therapy or not for asymptomatic/incidental lacunar infarction［J］.Stroke， 2023，54（7）：1954-1959.
［14］ Mu R， Qin X， Zheng W， et al. Hippocampal amide proton transfer values are associated with cerebral small vessel disease imaging markers and total burden： a community-based cross-sectional study［J］.Quant Imaging Med Surg， 2024，14（3）：2603-2613.
［15］ Chen Y， Zou H， Peng M， et al. Association between homocysteine levels in acute stroke and poststroke depression： a systematic review and meta-analysis［J］.Brain Behav， 2022，12（6）：e2626.
［16］ De Giuseppe R， Tomasinelli CE， Vincenti A， et al. Sarcopenia and homocysteine： is there a possible association in the elderly？A narrative review［J］.Nutr Res Rev， 2022，35（1）：98-111.
［17］ Li S， Jing J， Li J， et al. Elevated hs-CRP and symptomatic intracranial/extracranial artery stenosis predict stroke recurrence after acute ischemic stroke or TIA［J］.J Atheroscler Thromb， 2023，30（6）：601-610.
［18］ Cheng XD， Wang DZ， Zhang Q， et al. Predictive role of pre-thrombolytic hs-CRP on the safety and efficacy of intravenous thrombolysis in acute ischemic stroke［J］.BMC Neurol， 2023，23（1）：244-251.
［19］ Jung HW， Kim CY， Hong SP， et al. Randomized， multicenter， parallel，open，phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia［J］.J Clin Hypertens （Greenwich）， 2023，25（9）：828-844.
［20］ Lee JE， Yu SH， Kim SR， et al. Efficacy and safety of metformin and atorvastatin combination therapy vs. monotherapy with either drug in type 2 diabetes mellitus and dyslipidemia patients （ATOMIC）： double-blinded randomized controlled trial［J］. Diabetes Metab J， 2024，48（4）：730-739.
［21］ Zhou S， Chen R， Liu J， et al. Comparative effectiveness and safety of atorvastatin versus rosuvastatin： a multi-database cohort study［J］.Ann Intern Med， 2024，177（12）：1641-1651.
［22］ 叶淑英，郑应红，林舜贤，等.急诊一体化溶栓护理模式对急诊脑梗死患者急救效率，神经功能及短期预后的影响［J］.护理实践与研究，2024，21（7）：1095-1100.
［23］ Guo MN，Hao XY，Tian J，et al.Human blood metabolites and lacunar stroke：a mendelian randomization study［J］.Int J Stroke，2023，18（1）：109-116.
［24］ Wardlaw JM， Chabriat H， de Leeuw FE， et al. European stroke organisation （ESO） guideline on cerebral small vessel disease， part 2， lacunar ischaemic stroke［J］.Eur Stroke J， 2024，9（1）：65-68.
［25］ Sánchez-López E， Gómara MJ， Haro I. Atorvastatin-loaded peptide amphiphiles against corneal neovascularization［J］.Nanomedicine （Lond）， 2023，18（17）：1095-1108.
/
| 〈 |
|
〉 |